To find out whether the inhibition of Bcl-2 protein could attenuate established lung fibrosis during the post-inflammatory phase, we administered ABT-199 every 2 days from day 10 (Figure 5A). The gene discussed is BCL2; the disease is pulmonary fibrosis.